Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.
- Resource Type
- Article
- Authors
- Glintborg, B.; Kringelbach, T.; Bolstad, N.; Warren, D. J.; Eng, G.; Sørensen, I. J.; Loft, A. G.; Hendricks, O.; Hansen, I. M. J.; Linauskas, A.; Nordin, H.; Kristensen, S.; Lindegaard, H.; Jensen, D. V.; Goll, G. L.; Høgdall, E.; Gehin, J.; Enevold, C.; Nielsen, C. H.; Krogh, N. S.
- Source
- Scandinavian Journal of Rheumatology. Sep2018, Vol. 47 Issue 5, p418-421. 4p.
- Subject
- Language
- ISSN
- 0300-9742
The article focuses on a study conducted to analyze anti-drug antibodies (ADAs) and serum drug concentrations (sIFX) in arthritis patients who switched to CT-P13 from IFX. It refers to the inclusion of at least one blood sample of 173 IFX-naive patients and 373 switchers. The study found few changes in sIFX level and ADAs in patients who had received originator IFX for a median of 7 years.